{"id":"NCT03594747","sponsor":"BeiGene","briefTitle":"A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer","officialTitle":"A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-30","primaryCompletion":"2020-09-30","completion":"2023-04-28","firstPosted":"2018-07-20","resultsPosted":"2023-10-17","lastUpdate":"2024-10-26"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Tislelizumab","otherNames":["BGB-A317","Tevimbra"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"Tislelizumab + Paclitaxel + Carboplatin","type":"EXPERIMENTAL"},{"label":"Tislelizumab + Nab-paclitaxel + Carboplatin","type":"EXPERIMENTAL"},{"label":"Paclitaxel + Carboplatin","type":"ACTIVE_COMPARATOR"}],"summary":"An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).","primaryOutcome":{"measure":"Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019","timeFrame":"Through primary analysis data cut-off date of 06DEC2019 (up to approximately 1 year and 4 months)","effectByArm":[{"arm":"Tislelizumab + Paclitaxel + Carboplatin","deltaMin":7.6,"sd":null},{"arm":"Tislelizumab + Nab-paclitaxel + Carboplatin","deltaMin":7.6,"sd":null},{"arm":"Paclitaxel + Carboplatin","deltaMin":5.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["China"]},"refs":{"pmids":["33792623","38052215"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":120},"commonTop":["Anaemia","Alopecia","Neutrophil count decreased","White blood cell count decreased","Leukopenia"]}}